INTERPRETATION Absolute and normalized muscle volume of the injected muscle reduces after first BoNT-A exposure, and does not return to baseline volume by 25 weeks. Hypertrophy is seen in the soleus up to 25 weeks; the volume of the plantar flexor compartment is stable.
Botulinum neurotoxin A (BoNT-A) is a widely used treatment for focal spasticity, 1,2 a common motor impairment seen in children with cerebral palsy (CP). 3 BoNT-A has a well-documented safety profile, 4 and an array of positive clinical and functional outcomes. 1 With muscle volume in children with CP reduced compared with their typically developing counterparts, 5, 6 research has focused on the potential for BoNT-A exposure to further reduce muscle volume. Data from animal and healthy adult human studies have both found muscle atrophy (reduction in absolute muscle volume) in response to BoNT-A exposure. [7] [8] [9] [10] Muscle atrophy may significantly affect the muscle's functional ability.
Recent research has provided evidence to support the hypothesis that BoNT-A exposure among children with CP is associated with impaired muscle growth in the short term. BoNT-A exposure results in atrophy of between 4.47% and 20.5% of injected muscle, between 5 and 12 weeks after injection, depending on the muscle assessed and the measurement technique used. [11] [12] [13] While the pharmacological effect of BoNT-A washes out by approximately 12 weeks, 14 it is important to understand the long-term impact beyond this period. Studies have identified atrophy of injected psoas of 13.8% at 6 months, 11 and hypertrophy of injected gastrocnemius of 13% at 12 months 15 in children with CP, although the authors noted this rate of growth was reduced compared with typically developing children. Strength training has been suggested to redress the potential effect of muscle atrophy after BoNT-A. Williams et al. 16 reported that the combined intervention of BoNT-A and strength training improved outcomes over and above BoNT-A treatment alone, and no muscle atrophy was reported at 14 weeks after injection.
Although atrophy of the injected muscle is consistently found in the first 6 months after exposure, there is no clear consensus on the expected magnitude of this reduction.
This variation may stem from multiple factors, including measurement techniques, normalization, muscles assessed, ambulation status, BoNT-A dosage, and previous BoNT-A exposure (which has been found to be an important factor in predicting atrophy in animal models). 8, 9 While some of these factors were well described in the aforementioned studies, others were not, clouding interpretation.
For a greater understanding of the global impact of the targeted intervention, assessment of the synergistic and antagonistic muscles is required. This has been shown to be true in animal models, with significant alterations in non-injected muscle still apparent 6 months after injection. 9 To the authors' knowledge, only one study has done this in children with CP, who were serial BoNT-A receivers, reporting a significant increase in soleus volume at 5 weeks after gastrocnemius injection. 13 This was suggested to be evidence of compensatory hypertrophy, to improve function of the plantarflexor group. The biarticular gastrocnemius acts as both a plantarflexor and a knee flexor. 17 So far no research has investigated the possibility of compensatory hypertrophy of the hamstrings to maintain knee flexion function. Such assessment of the associated muscles is important in contributing to the understanding of the functional implications of alterations in muscle growth.
The objective of this study was to assess change in muscle volume, using magnetic resonance imaging (MRI), of the injected and synergistic muscles, after the first exposure to clinically given BoNT-A in children with CP. Muscle volume changes were tracked over a 6-month period, with assessments at 4, 13, and 25 weeks, relative to baseline (pre-BoNT-A) volume. It was hypothesized that the injected gastrocnemius muscle would show atrophy at each time point, with the greatest atrophy expected at 13 weeks after injection, while hypertrophy would be found in the synergistic muscles of the soleus and medial hamstring group at each time point.
METHOD
This was an observational prospective cohort design. BoNT-A for focal spasticity management in children with CP is now best practice care; 2 therefore case-control or randomized controlled trials were not ethically appropriate. Baseline assessments were conducted before BoNT-A exposure, with follow-up assessments conducted at 4, 13, and 25 weeks after injection. These time points correspond to peak neurological effect, 14 period of clinical usefulness, 2 and recommended consideration for repeat injection. In total, 22 patients were identified as eligible and invited to participate (Fig. 1) . Informed consent was provided for 13 participants, and 11 (eight males, three females) completed baseline and at least one follow-up assessment. Participants were aged between 5 and 13 years (8y 10mo, SD 3y 1mo), and were classified in Gross Motor Function Classification System level I (n=7) or II (n=4). Seven participants were classified with diplegia, four with hemiplegia. All participants had spasticity, as measured by the Modified Tardieu Scale, 19 of the gastrocnemius with a mean dynamic muscle length of 18.3°(SD 10.8) plantarflexion, and a mean static muscle length of 4.8°(SD 5.4) dorsiflexion. The average height of the participants was 131.2cm (SD 11.53), and average weight was 31.8kg (SD 6.3).
Participants received ultrasound-guided injections of BoNT-A (Botox; Allergan, Irvine, CA, USA) to the targeted muscle, with a total dose of between 60 and 340 units of BoNT-A (1.6-12U/kg), using 1mL to 2mL dilution (mean 1.47mL, SD 0.51). All participants received BoNT-A to the affected gastrocnemius (18 legs injected, 1.4-4.8U/kg). Other muscles injected were the medial hamstrings (six legs, 1.4U/kg), tibialis posterior (two legs, 1U/kg), and rectus femoris (two legs, 0.6U/kg).
Timing for baseline assessment was a mean of 1.17 weeks (SD 1.10) before the first BoNT-A injection. Follow-up assessments were conducted at 4.3 weeks (SD 1.1), 13.1 weeks (SD 1.2), and 24.7 weeks (SD 1.9). Seven participants completed all follow-ups, while four completed between one and two follow-ups ( Fig. 1 ). All participant data were used in the analysis assessing lower-leg muscle volume and functional results, with sample sizes outlined in Figure 1 . For the analysis of hamstring muscle volume, only those who did not have upper leg injections were assessed: 12 legs were assessed at baseline, nine legs at 4.3 weeks, nine legs at 13.1 weeks, and 11 legs at 24.7 weeks.
Clinical outcomes, including technical response at the 6-week clinical follow-up, further interventions, and adverse events, were noted. A technical response was taken as a reduction in the dynamic component of muscle length (the difference between the angle of muscle reaction and passive range of motion detected by the Modified Tardieu Scale) 18 What this paper adds
• Muscle atrophy after first botulinum neurotoxin A (BoNT-A) exposure in children with cerebral palsy is noted.
• Mild BoNT-A-induced muscle atrophy is still apparent 6 months after BoNT-A exposure.
• Hypertrophy is evident in soleus after gastrocnemius BoNT-A exposure.
• Total plantarflexor volume is unchanged.
of more than 5°. To assess functional mobility capacity, the 6-minute walk test 20 and Timed Up and Go 21 assessments were used. A 1.5T whole-body MRI unit (Magnetom Sonato Maestro Class, Siemens Medical Solutions, Erlangen, Germany) was used to acquire axial scans from the iliac crest to the ankle malleoli, using a T1-weighted spin-echo sequence. Participants lay prone with their hips and knees in a neutral position, with ankles in a relaxed posture. Positioning was maintained passively.
Images were collected using a repetition time of 572ms and an echo time of 13ms. Slices were 5mm thick, with an average slice increment of 10.2mm (10.0mm-12.5mm). Scan matrix size and field of view were optimized for each participant, with an average lower-leg matrix of 256.0mm9124.5mm and field of view of 333.1mm, and an average thigh matrix of 256.0mm9129.0mm and field of view of 343.4mm. The mean number of slices for the lower leg was 35.2 (27-43 slices), and for the thigh was 37.9 (27-50 slices).
MRI images were processed using Mimics (version 16.0; Materialise, Leuven, Belgium). Muscles were manually traced by a single, blinded assessor (CA). Bilateral muscle volume assessments were made for participants with diplegia, while only the affected side was assessed for participants with hemiplegia. Muscles segmented and used for analysis were the gastrocnemius (medial and lateral heads), soleus, tibialis anterior, and hamstrings (biceps femoris, semitendinosus, and semimembranosus). Muscle volume was calculated as the product of the number of voxels in each reconstruction and the voxel size. Muscle volumes were analysed both as absolute volumes and as normalized volumes to account for skeletal growth over the study period. For this, the lower-leg muscle volume was normalized to tibia length, and hamstring volume was normalized to femur length. 13 The repeatability of this method has been previously reported, with the intraclass correlation coefficient for interrater and intrarater reliability being greater than 0.94 and 0.92 respectively. 22 For the single assessor in this study (CA), intrarater repeatability was assessed on a random selection of five participants. For these participants, 10 muscles were assessed and found to possess excellent repeatability (intraclass correlation coefficient 0.998), and a mean measurement difference of 1mL.
Statistical analysis was conducted in Stata (StataCorp, College Station, TX, USA) to compare each follow-up assessment with baseline measurements. For all functional and muscle volume data, mixed model analyses were used to account for repeated measures over time and missing data points, as well as correlation between left and right limbs for children with diplegia. Predicted means are presented, with 95% confidence intervals, and one-tailed p-values. Statistical significance was accepted at a=0.05. 
RESULTS Participants
All participants showed a technical response to BoNT-A, with the mean difference between the angle of muscle reaction and passive range of motion measurements of the gastrocnemius reducing from 23.1°(SD 9.5) to 12.2°(SD 6.6) at the 6-week clinical follow-up, where the mean dynamic muscle length of the plantarflexors was 5.8°(SD 7.1) plantarflexion and mean static muscle length was 6.5°( SD 4.6) dorsiflexion. No adverse events were reported. Nine participants went on to receive further BoNT-A at an average of 26.7 weeks (SD 2.0). Two participants were deemed not to require further intervention at their 6-month clinical follow-up, and had not received any further intervention by their 12 month follow-up. Significant increases in distance covered in the 6-minute walk test were identified at 13 and 25 weeks, while significant decreases in the Timed Up and Go time were identified at all time points after BoNT-A exposure (Table I) .
Muscle volume
Absolute changes in muscle volume are presented in Table II . The injected gastrocnemius showed significant atrophy at 4, 13, and 25 weeks after injection, equating to a 5.9%, 9.4%, and 6.8% reduction in muscle volume respectively. The soleus showed significant hypertrophy at 4, 13, and 25 weeks of 6.0%, 7.7%, and 10.8% respectively. The total plantarflexor group showed significant hypertrophy at 25 weeks after injection of 5.1%. No changes were found in the tibialis anterior. Of those who received gastrocnemius injections only, the hamstrings showed significant hypertrophy at 4 (2.1%), 13 (5.7%), and 25 (7.0%) weeks. Normalized muscle volumes are presented in Table III . The gastrocnemius showed significant reductions of 6.7%, 10.7%, and 9.8% at 4, 13, and 25 weeks respectively. The soleus showed significant increase in normalized muscle volume of 5.4%, 6.1%, and 7.4% at 4, 13, and 25 weeks respectively. No changes were identified in the total plantarflexor volume or the tibialis anterior. Of those who received gastrocnemius injections only, the hamstring group showed a significant increase in normalized muscle volume at the 4-week follow-up only of 5.5%.
DISCUSSION
The results support the hypothesis that muscle volume is reduced after BoNT-A exposure. In the injected gastrocnemius, absolute muscle volume was found to be reduced at all time points relative to baseline, indicating true muscle atrophy. However, a more accurate understanding of the magnitude muscle volume changes over time in paediatric populations comes from assessment of change in muscle volume relative to limb growth. Indeed, in typically developing children one can expect hypertrophy over time, with the absolute muscle volume increasing, 22 allowing maintenance of the functional capacity of a muscle as the child grows. Normalizing the muscle to bone length allows skeletal growth to be taken into account. 13 When assessing alterations of normalized muscle volume of the injected gastrocnemius, reductions were found at all time points.
On the basis of previous research, and understanding that the period of clinical usefulness of BoNT-A is 12 to 16 weeks, peak atrophy was hypothesized to occur at 13 weeks after injection. The findings support this, with the normalized muscle volume showing the greatest reduction (À10.7%) at 13 weeks. This suggests muscle recovery does occur once the pharmacological effect of the BoNT-A wears off, but that full recovery is not achieved by 25 weeks.
While normalized muscle volume provides some insight into the functional volume change, the gastrocnemius is not the only muscle that acts as a plantarflexor. As hypothesized, normalized soleus volume showed significant increase at follow-up assessments, resulting in no changes to total plantarflexor volume at any stage. This finding suggests the functional strength capacity of the plantarflexors may be maintained despite gastrocnemius atrophy. However, given the poor relationship between muscle size and measures of muscle strength in children with CP 6 and the impact of BoNT-A exposure on muscle histology, 23 further research is required to confirm this.
The observed hypertrophy of the soleus may be a compensatory mechanism to maintain the role of plantarflexion at the ankle. However, as the gastrocnemius is a biarticular muscle, a reduction in volume also affects its role as a knee flexor, 17 which may be particularly relevant for children with CP who often experience spasticity and functional alterations of both the knee flexors and ankle plantarflexors. This is the first study, to the authors' knowledge, to assess hamstring changes in response to gastrocnemius injections and show absolute hypertrophy of the hamstrings at all time points; although, once normalized to femur length, muscle volume only demonstrated hypertrophy at 4 weeks. In simulations of the kinetics of healthy adult knees, a reduction in gastrocnemius force has been found to result in a substantial increase in medial hamstring force to maintain the same knee flexion moment. 17 This suggests there may be reduced capacity to generate power at the knee as the atrophy in the gastrocnemius (and potential reduction in force generating capacity) is not compensated by hypertrophy in the hamstrings. Although the sample size was small, this study met the power required for statistical significance. However, the small sample size of children who received injections to the hamstrings prevented a full statistical analysis of this group, thus limiting the application of these results to single-level BoNT-A cases only. While the relationships between limbs in children with diplegia were statistically controlled for, the inclusion both of children with diplegia and of those with hemiplegia may pose a further limitation, as research suggests notable differences in response to BoNT-A injections and reinjection schedules with CP subtype. 24 This study was also limited by the lack of a comparison group; therefore causal links between BoNT-A exposure and alterations in non-injected muscle groups cannot be established. While clinical outcomes were assessed by clinicians, informal reporting of goal-based outcomes, and functional assessments (Timed Up and Go test and 6-min walk test), future research would benefit from a more comprehensive assessment of functional outcomes including muscle strength.
The findings of this study support previous research showing atrophy in the injected muscle. The magnitude of this absolute reduction was less than that identified in previous research. At 4 and 13 weeks after injection, the current study identified reductions of 5.9% and 9.4%, compared with 11.2% and 17.6% by Park et al., 12 a difference attributed to the measurement method used, with Park et al. 12 using muscle thickness as a substitute for muscle volume. At 25 weeks, the 6.8% reduction in muscle volume is notably less than the 13.8% reduction found by Van Campenhout et al. 11 This discrepancy may be explained by the different muscle assessed (the psoas muscle, markedly different in its operating characteristics compared with the gastrocnemius) and the ambulatory status of the participants (which was not stated).
The results of this study suggest a larger reduction in magnitude of injected muscle volume compared with that found in previous research by Williams et al. 13 With the muscle of interest and the measurement technique used being identical, this may be attributed to the BoNT-A history of the participants. In the current study, all participants were toxin-naive, whereas participants in the previous study received on average 8.9 (range 2-15) injections before enrolment. This suggests that first exposure to BoNT-A results in greater atrophy compared with subsequent exposure, a finding that is supported by animal models. 8 The larger reduction in the injected gastrocnemius in this study was offset by a larger magnitude increase in normalized soleus volume, resulting in no change in the total plantarflexor volume, which replicates the findings of the previous body of work. Williams et al. 13 did not conduct further follow-up assessments, so the rate of recovery cannot be compared without further research.
No previous research has assessed the impact of gastrocnemius BoNT-A exposure on the hamstrings in children with CP. While absolute hypertrophy (7.0%) was found at 25 weeks, it is notably less than the hypertrophy seen in typically developing children over the same period. 22 However, this difference may reflect a reduced rate of muscle growth in children with CP regardless of intervention. Although longitudinal data are not currently available on the natural progression of muscle growth in toxin-naive children with CP, cross-sectional research has found children with spastic CP demonstrate reduced muscle volume from the age of 15 months, 25 and that muscle volume correlates with age, 26, 27 which is evidence of a reduced rate of muscle development. This study has found that, at 25 weeks, muscle volume has not fully recovered, consistent with previous animal 9, 27 and human research. 11 Previously published data by Barber et al. 15 found that, at 52 weeks, injected gastrocnemius showed a 4.8% increase in normalized volume (calculated on the basis of presented fibula lengths) in toxin-naive children with CP. Combined, these results suggest that gastrocnemius atrophy recovers between 25 and 52 weeks. Indeed, Barber et al. 15 found that although no significant differences in muscle volume were found at baseline or 52 weeks after injections in children with CP who received a single BoNT-A injection, those who received three injections showed slower growth over 52 weeks compared with those who received three injections over the same period (1.1% growth compared with 4.8% in the single injection group, calculated on the basis of presented fibula lengths).
Understanding when full muscle volume recovery after BoNT-A exposure occurs is important when considering the timing of repeat injections and the functional and long-term clinical consequences this may have. BoNT-A has a major role in reducing hypertonia and increasing function, as demonstrated in these children with CP; however, it may be important to consider the recovery profile of the muscle when planning serial treatments, for example alternating injection sites and allowing longer intervals between reinjection.
